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Abstract. OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment 
with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric 
kidneys. Rejection was controlled in 75% of patients treated, often after high-dose steroid therapy had failed. 
Rejection recurred during the 17 -month follow-up period, after completion of 0 K T3, in only 25% of the patients who 
had responded. The safety and effectiveness of this monoclonal therapy, added to ciclosporin and steroids, has been 
established in this study. 
Introduction 
Numerous clinical studies in renal, hepatic and car-
diac transplantation have shown the value of antilym-
phocyte globulin (ALG) given prophylactically with aza-
thioprine and steroids [1-4] or for the specific purpose of 
reversing an established rejection [5-7]. However, several 
inherent properties of conventional ALG prevented its 
full exploitation [8, 9]. ALG could not be fully standard-
ized from batch to batch; it frequently contained irrele-
vant antibodies directed against formed blood elements 
other than lymphocytes, and the amount of heterologous 
protein administered was excessive. Avoidance of these 
disadvantages became possible with the development of 
monoclonal antibody preparations with defined speci-
ficities using the hybridoma technology developed by 
Kohler and Milstein [10]. 
Much of what has been learned about lymphocyte 
functions in the past few years has led to the hope that 
subsets of the lymphocyte popUlation could be speci-
fically manipulated by monoclonal antibodies for thera-
peutic purposes. Antigen recognition and induction of 
activation of mature T lymphocytes appear to reside 
Supported by research grants from the Veterans Administration, 
by NIH grant AM-29961, and a grant from the Competitive Medical 
Research Fund-Richard King Mellon Foundation. 
within the T3/antigen receptor complex on the T cell 
surface [11, 12]. Modulation of the T3/antigen receptor 
complex has been shown to occur following antigen 
stimulation [13] and with murine monoclonal antibodies, 
such as Orthoclone OKT 3, directed against one compo-
nent of the T3 antigen [14]. In vitro studies have demon-
strated an effect of OKT3 on both the cytotoxic and the 
proliferative capacities of T cells [15, 16]. In vivo, OKT3 
has been shown to have a profound effect on both the 
primate [17] and the human [18] immune response. 
In 1981, Cosimi et al. [18, 19] reported the first clinical 
trials with OKT3 for the treatment of acute renal allograft 
rejection. In those studies, in other similar pilot investiga-
tions [20] and in a multicenter clinical trial [21] OKT3 was 
reported to reverse acute rejection of kidney transplants 
significantly better than treatment with high-dose ste-
roids. The major drawback was a high incidence of recur-
rent rejections when the patients were returned to main-
tenance therapy with azathioprine and prednisone. 
We report here results of our pilot trials of OKT3 
therapy in 62 recipients of cadaveric kidneys or livers 
whose baseline immunosuppression was with ciclo-
sporin and steroids. A ten- to 14-day course ofOKT3 was 
generally started because rejection had developed in 
spite of cicIosporin-steroid therapy, but in several liver 
recipients, OKT3 was begun because optimal therapy 
with ciclosporin could not be given in the face of poor 
postoperative renal function. 
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Fig. 1. Clinical course of a cadaveric kidney recipient whose 
graft underwent an initial period of acute tubular necrosis, with a 
beginning subsequent diuresis that was interrupted by rejection. 
Arrows: I g methylprednisolone. CyA = Cic1osporin. 
Materials and Methods 
Case Material 
The patients were treated between August 1984 and May 1985 
with follow-up through January 1986. 
Cadaveric Renal Transplantation. The average age of the ten 
renal recipients was 36.0 ± (SD) 16.0 years (range, 24-55 years). Four 
of the ten had diabetes mellitus with diabetic nephropathy as the 
cause of renal failure. Nine were primary graft recipients, and the 
10th had undergone retransplantation after the primary graft had 
been rejected 36 months earlier. Except for avoidance of ABO blood 
group incompatibilities and positive Iymphocytotoxic antibody 
crossmatches, donor-recipient matching was random. At the HLA 
A, B, and DR loci, an average of 1.1 antigens out of a maximum of 6 
were matched. 
Orthotopic Liver Transplantation. Twenty-two of the 52 liver 
recipients were in the pediatric age range of6 months to 17 years and 
averaged 6.9±(SD) 4.5 years. The age of the 30 adults averaged 
39.1 ± 8.6 years (range, 19-54 years). Forty-three (83%) of the 52 
patients were bearing their first grafts, and the other 9 had under-
gone retransplantation. 
All of the grafts used for hepatic recipients were selected without 
knowledge of the HLA types. At the HLA A, B, and DR loci, the 
antigens matched averaged 1.2 out of a possible 6. Positive cytotoxic 
crossmatches were present in 3 (9%) of the 34 cases in whom the test 
was performed. In 6 patients, there was a breach of the conventional 
guidelines of ABO blood group compatibility, which were originally 
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Fig. 2. Clinical course of liver recipient OT 495, who developed 
biopsy-proved rejection after 10 days while undergoing ciclo-
sporin(Cy A)-steroid therapy. Note that ciclosporin was given at first 
by both intravenous (dark shading) and oral (no shading) routes. 
TBIL= Total bilirubin; SGOT= serum glutamic-oxaloacetic trans-
aminase; steroid bolus: solid bars = methylprednisolone, intraven-
ously; open bars = hydrocortisone intravenously. 
defined in kidney transplantation [22]. The resistance of the liver to 
hyperacute rejection from preformed antibody states has been 
noted before [23, 24). 
In 3 patients whose first liver grafts failed in spite of OKT3 
therapy, the murine immunoglobulin was used again after retrans-
plantation. The results of treatment in these 3 patients, who were 
given a second course ofOKT31, 2, and 3 months after a first course, 
were analyzed separately from the results obtained with the 52 first 
courses. 
Primary Immunosuppression 
Kidney Transplantation. For kidney recipients, an oral dose of 
17.5 mg ciclosporin/kg body weight was given 5-6 h preoperatively. 
Postoperatively, the same daily amount was provided in divided 
doses every 12 h. Four patients who did not have time for oral 
preoperative medication, or who could not eat postoperatively, 
were given intravenous ciclosporin for a few days in doses of 4 to 
6 mg/kg/day. Postoperatively, ciclosporin therapy was monitored 
by frequent determinations, with radioimmunoassay of the whole-
blood drug level in samples obtained at trough, just before adminis-
tration of the next dose [25). The whole-blood concentrations were 
kept in the range of 750-1,000 ng/ml if renal function remained or 
OK T3 in Reversal of Allograft Rejection 
became satisfactory. If good function was not obtained, potential 
nephrotoxicity was suspected and the dose of ciclosporin was ad-
justed downward after 10 days, so that the whole-blood trough 
concentration would fall to the 400-600 ng/ml range or slightly 
lower (fig. I). 
Steroids were also given systemically [26]. With revasculariza-
tion of the kidney allografts, I g methylprednisolone was adminis-
tered intravenously in the operating room, and subsequently, a 
5-day burst of methylprednisolone was started intravenously or 
orally, beginning with 200 mg on the 1st postoperative day. The 
prednisone doses were reduced by 40 mg/day until the 6th postop-
erative day, when a maintenance level of 20 mg was reached. If 
rejection was thought to have developed in spite of this therapy, the 
patient was submitted to a second 5-day steroid course (fig. I). Those 
who were refractory to this therapy or who responded only tempo-
rarily became candidates for OKT3 therapy. Their rejections were 
therefore considered 'steroid-resistant'. 
Liver Transplantation. The principles of the ciclosporin-steroid 
therapy for liver transplant cases were the same as for renal recip-
ients, but the details were vastly more complicated. Most liver 
recipients required intravenous ciclosporin and intravenous ste-
roids for several days postoperatively. With resumption of dietary 
intake, the absorption of oral ciclosporin was generally unreliable 
and unpredictable, necessitating the overlapping of intravenous 
therapy (fig. 2), sometimes for periods of weeks before adequate 
blood levels could be sustained with the oral route alone [27, 28]. The 
achievement of therapeutic blood levels of ciclosporin was made 
difficult in many patients by the concurrent incipient renal failure, 
which is a common precondition in hepatic transplant recipients 
[29, 30] and which can be aggravated by ciclosporin. As a conse-
quence, the steroid component of therapy was individualized more 
than with the renal recipients in an effort to compensate for irregular 
ciclosporin schedules. 
Indications and Timing ofOKT3 Therapy 
Renal Transplantation. Rejection was the reason for OKT3 treat-
ment in all 10 patients. Therapy was begun a median interval of 25 
days after transplantation (range 10-167 days). Rejection was diag-
nosed from the usual multiple lines of evidence, not all of which 
were present in every case. These included the physical signs of 
wound tenderness and graft swelling; secondary deterioration of 
grafts that had functioned well immediately postoperatively; failure 
of five grafts with poor initial function to recover from their pre-
sumed acute tubular necrosis, and secondary deterioration of allo-
grafts that were recovering from acute tubular necrosis (fig. I). Serial 
radionuclide scans showed the progressive reductions in renal 
blood flow and function that have been associated with rejection [31, 
32]. Needle biopsies of the grafts were obtained in 3 patients prior to 
starting OKT3 therapy, 10, 48, and 167 days postoperatively. Histo-
logically, these biopsies contained the mononuclear cell infiltra-
tions and edema of acute rejection, as well as evidence of chronic 
rejection in a graft that had been in place for 167 days. Follow-up 
biopsies after OKT3 therapy were not obtained. 
Liver Transplantation. The 52 hepatic allograft recipients were 
treated with OKT3 from 2 to 460 days after transplantation. Of the 41 
patients in whom liver biopsies were obtained, 36 were done just 
before or shortly after starting monoclonal therapy. In the other 5 
patients, liver biopsies were done 2-4 weeks prior to initiation of 
OKT3 therapy. In analyzing the results, the liver-transplant recip-
ients were stratified into three groups: 
21 
Table I. Indications for OKT3 therapy in hepatic allograft recip-
ients' 
Group I 
Group 2 
Group 3 
Total 
Number of Renal 
patients failure 
18 
22 
12 
52 
8 
o 
o 
8 
Poor initial 
graft function 
9 
3 
o 
12 
Rejection 
152 
21 
12 
48 
As documented by clinical and laboratory criteria (see text). 
See table II for factors associated with rejection in group 1. 
- Group 1: OKT3 treatment started less than 10 days postopera-
tively; 
- Group 2: 0 KT3 treatment started 10 days to 3 months postop-
eratively; 
- Group 3: 0 KT3 treatment started more than 3 months postop-
eratively. 
Group I. Therapy in this group was started a median of 6 days 
following transplantation. Eight of the eighteen patients treated 
during the first 9 days after transplantation had poor renal function 
(table I), which precluded aggressive treatment with ciclosporin 
(fig. 3). When present, renal failure was always associated with 
hepatic dysfunction. Contributing factors leading to liver dysfunc-
tion were thought to be ischemic injury of the graft and/ or rejection, 
but an absolute differential diagnosis between these potentially 
coexisting factors was difficult to make. In several patients, liver 
biopsies were either deferred until shortly after initiation of OKT3 
therapy or not done because of their unstable clinical condition or 
because their coagulation studies were severely deranged. The asso-
ciations of hepatic and renal complications, as these could be 
classified from clinical events, hepatic biopsies, and autopsy tissues, 
are summarized in table II. 
Six of the ten patients in group 1 who had hepatic dysfunction 
without renal failure had clinical and histologic evidence of liver 
rejection. Three others had a combination of ischemic injury and 
rejection, which explained persistent liver function abnormalities. 
Only I patient had primary hepatic graft dysfunction alone. 
Group 2. The decision to use 0 KT3 therapy between 10 days and 
3 months was based invariably upon a secondary deterioration of 
hepatic function tests after fair to good function had been achieved 
during the first 9 days. Among the 22 patients in this group, OKT3 
was started a median of21 days posttransplantation. Before starting 
OKT3, hepatitis secondary to B virus infection was ruled out with a 
hepatitis serologic screen. Ultrasound and/or angiographic studies 
were used to prove hepatic arterial and portal vein patency. Biliary 
obstruction was ruled out with ultrasonography, computerized axial 
tomography, radio nuclide imaging techniques, or cholangiography. 
Liver biopsies, verifying acute cellular rejection (fig. 4), were ob-
tained in 21 of the 22 patients in this group. 
Group 3. Twelve recipients have given a course of OKT3 from 3 
to 16 months after transplantation (median, 230 days posttransplan-
tation) because of a delayed deterioration of liver function (fig. 5). 
The workup, including a percutaneous liver biopsy in all group 3 
patients, was the same as in group 2. If histopathologic findings of 
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463, whose OKT3 course was started after 9 
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cluded giving therapeutic doses of ciclosporin 
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acute rejection were found, a steroid bolus was given and eventually 
a course of OKT3 was started, even if there were morphologic 
stigmata of chronic rejection, including loss oflobular bile ductules, 
arteriolar thickening. and portal fibrosis (fig. 6). 
OKT3 Administration and Precautions 
The intravenous dose of OKT3 was 5 mg in adults and 2.5 mg in 
children, delivered by syringe push over 2-5 min. Premedication 
with 50 mg i.v. diphenhydramine and 500-1,000 mg i.v. hydrocorti· 
sone was carried out approximately 1 h prior to administration of the 
first two doses. The patients were watched continuously by a physi-
cian for the first 2 h. Wheezing, dyspnea, cardiovascular instability. 
and fever were considered potential precursors of more serious 
reactions. 
Because severe pulmonary edema has been reported in patients 
with preexisting fluid overload [21], this factor was excluded or 
treated prior to treatment with OKT3. Furthermore, monoclonal 
antibody therapy was never undertaken without the capability for 
emergency endotracheal intubation and ventilatory support. The 
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Table II. Complex nature of coexisting indications for OKT3 
therapy in group I patients 
Indication Number 
of patients 
Renal failure alone 0 
Renal failure plus primary graft dysfunction 2 
Renal failure plus rejection 3 
Primary graft dysfunction alone 
Primary graft dysfunction plus rejection 3 
~~~~e 6 
Renal failure, primary graft dysfunction plus rejection 3 
Total 18 
a 
b 
OKT3 in Reversal of Allograft Rejection 
Fig. 4. Histologic findings of cellular rejection typical in group 2 
liver patients consist of portal mononuclear cell infiltration with 
damage to bile duct epithelium and endothelium of vessels (arrow). 
The patient, OT 407, had a repeat biopsy after therapy (fig. S). 
ax125. bx315. 
steps for the treatment of anaphylactoid reactions, which included 
bronchospastic reactions, severe cardiovascularinstability, and pul-
monary edema, were throughly impressed upon all physicians in 
attendance. The sequence began with 1 g hydrocortisone intrave-
nously, progressed to an epinephrine infusion if necessary, and 
concluded with intubation and ventilatory support. This chain of 
events never evolved in any of the kidney patients, but I of the 52 
liver recipients required intubation and an epinephrine drip for 24 h. 
Adjustments in prednisone therapy from the maintenance level 
were not usually made during the 10- to 14-day period of OKT3 
therapy. In contrast, efforts were made to adjust the ciclosporin 
doses to those that would be kept permanently, using daily measure-
ments of ciclosporin blood levels for guidance. The objective was to 
have all factors of the maintenance immunosuppression stable at 
the end of therapy (fig. 3). Since ciclosporin was often suspected as 
the cause of renal dysfunction, downward adjustments of ciclo-
sporin dose were common at the beginning of therapy, with restora-
tion to higher levels toward the end when renal function parameters 
stabilized. 
23 
Immunologic Monitoring of Peripheral Blood 
The following immunologic parameters were also studied in the 
majority of adult recipients: serum OKT3 levels, presence of anti-
murine antibodies, and T cell subpopulations. OKT3 and antimu-
rine antibody titers were determined by enzyme-linked immunosor-
bent assay (ELISA) using kits furnished by Ortho Pharmaceutical 
Corporation, Immunobiology Division, according to previously 
reported methods [33]. 
T-cell subpopulation determinations were done by flow cytome-
try on a FACS IV [Becton Dickinson, Mountainview, Calif.], using 
slight modifications of methods described previously [34]. The fol-
lowing fluorescein-labeled anti-T-cell surface marker monoclonal 
antibodies were used: T3 (OKT3, Leu 4), T4 (OKT4, Leu 3 a+b), 
and TS (OKTS, Leu 2a). The OKTseries was purchased from Ortho 
Diagnostics; the Leu series was purchased from Becton Dickinson. 
At least 5 x 104 cells were analyzed for each monoclonal antibody 
determination. 
Histopathologic Studies in Liver Recipients 
Biopsy specimens were fixed in neutral buffered formalin and 
routinely stained with hematoxylin and eosin, trichrome, and reticu-
lin stains. The biopsy slides were reviewed by three pathologists 
(AJD, RJ, KAP) in a blind fashion, independent of clinical correla-
tion. A consensus pathologic diagnosis was given for each speci-
men. There were minor differences of opinion among the patholo-
gists in only 2 cases. 
The following histologic criteria were used for the pathologic 
diagnosis of acute hepatic rejection (fig. 4): 
- A predominantly mononuclear portal tract infiltrate in which 
the inflammatory infiltrate consisted of 50-60% mononuclear cells 
intermixed with polymorphonuclear cells and eosinophils; 
- Characteristic localization of the inflammatory cells around 
and beneath the swollen endothelium of portal capillaries and small 
veins, with infiltration and damage of the epithelium of small bile 
ductules (the number of 'damaged' bile ductules and the degree of 
damage generally increased with time. The most severe changes, 
with ductular loss, were seen in 'chronic rejection'). 
- Absence of the following histologic findings: significant pan-
lobular inflammation; piecemeal necrosis; cholangiolar prolifera-
tion; disarray, with ballooning and spotty individual hepatocyte 
necrosis; and prominent Iymphohistiocytic infiltration of the he-
patic lobule, with inflammatory cell destruction of hepatocytes. 
(The foregoing are not prominent features of rejection under im-
munosuppression and suggest alternative diagnoses, such as viral 
hepatitis or large-duct obstruction.) 
A diagnosis of chronic hepatic rejection (fig. 6) was made if there 
was evidence of 
- The obliterative arteriolar lesions that have been found in liver 
as well as other solid organs [35, 36]; 
- Loss of intrahepatic bile ducts, often with only a mild periduc-
tal and intraductal chronic inflammatory infiltrate; 
- Portal fibrosis, especially if linkage had occurred between 
portal tracts or central veins; 
- The above must be accompanied by an absence of lobular 
changes as outlined earlier for acute rejection. 
In 24 cases in which the pretreatment biopsies showed ceIl-medi-
ated rejection, follow-up biopsies were obtained from 2 days before 
completion to 5 weeks after completion of OKT3 therapy. Nineteen 
of these 24 follow-up biopsies were done within 2 weeks after 
stopping the monoclonal therapy. 
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Fig. 5. Clinical course ofliver recipient OT 320 treated with OKT3 for acute rejection 14 months after transplantation. Abbreviations and 
symbols, same as in figure 2. 
Definition o/Therapeutic Response 
Kidney Recipients. A full response to OKT3 therapy was defined 
as a return of serum creatinine to less than 2 mg/dl (SI units: 
176.8 Ilmol!l) during or within 2 weeks after completion of therapy. 
In addition, reversal of graft tenderness and swelling, improvement 
in the radionuclide flow scans, and diuresis were generally seen. A 
less marked but definite improvement was termed a partial re-
sponse. 
Liver recipients. A complete response to therapy in the liver 
recipients during OKT3 therapy or within the first 2 weeks following 
its completion was defined as return of abnormalities in liver func-
tion to normal or near normal, with objective improvement in the 
histologic findings in follow-up biopsy studies, when these were 
obtained. Partial response was defined as improvement ofbiochem-
ical parameters, with or without objective improvement in histol-
ogy. Patients were assigned to the no-response category if there was 
no improvement or if there was worsening of biochemical and 
histologic parameters. 
Results 
Kidney Transplantation 
Period of Follow-Up. The mean follow-up of the 10 
renal-transplant recipients after treatment with OKT3 is 
13.6 ± (SD)2.0 months (range, 10-17 months). 
Morbidity. There were no life-threatening side effects, 
such as pulmonary edema, attributable to administration 
of OKT3 in renal patients. Fever was the most common 
side effect, and was seen in 80% of the patients during 
OKT3 therapy. No major infections occurred, but 40% 
experienced minor infections, of which the most com-
mon was cutaneous herpes simplex (table III). One pa-
tient had a cecal perforation during the course of OKT3 
therapy, necessitating right ileocolectomy. However, the 
patient recovered and did not lose allograft function. The 
cecal perforation was not considered a complication of 
OKT3 therapy. 
Mortality. All of the renal patients treated with OKT3 
were alive at the end of the follow-up period. 
Response to OKT3 Therapy. Resolution of the physical 
findings of rejection, an increase in urine output, and a 
progressive decline in serum blood urea nitrogen (BUN) 
and creatinine were seen in 8 of the 10 patients. Four 
(40%) had a full response and four (40%) had a partial 
response. Rebiopsy was not performed in any of these 
patients. In one failure, the transplanted kidney was 
found at graft nephrectomy to have undergone humoral 
mediated rejection, as documented by pathologic find-
ings. The other failure was from continued, uncontrolled, 
cell-mediated rejection. Reversal of rejection, when this 
occurred, usually was evident within 2-3 days, but con-
tinued improvement was seen up to 2 weeks following 
completion of OKT3. 
Recurrence of Rejection. Following completion of 
a 
b 
OKT3 in Reversal of Allograft Rejection 
Fig. 6. Patient OT 377. Histologic findings of chronic rejection. 
Note paucity of bile ducts and fibrosis in portal tracts. a x 125. 
bx315. 
monoclonal therapy, the patients were maintained on a 
chronic ciclosporin-steroid regimen in the same manner 
as other renal recipients. Two patients slowly rejected 
their grafts 2.5 and 6 months after a partial response to 
OKT3. With a mean follow-up of 15.5 months, recurrent 
rejection has not been noted in the other 6 patients who 
had responded to OKT3 therapy. Thus, 60% of these 
patients with steroid-resistant rejection have achieved 
long-term graft function. Five of the six patients have a 
mean creatinine of I.7 ± (SD) 0.5 mg/ dl (SI units: 
150.3 ± 44.2 llmol/l); the 6th has a stable creatinine of 
2.4 mg/ dl (SI units: 212.211mol/l), with a BUN of III mg/ 
dl (SI units: 39.6 mmol/l). 
Liver Transplantation 
Period of follow-up. The mean follow-up is 
12.2±(SD) I.7 months after treatment with OKT3. The 
25 
Table III. Morbidity and mortality in 10 kidney-transplant recip· 
ients receiving OKT3 therapy 
Morbidity 
Mortality 
Fever 
Hemodynamic instability 
Gl symptoms 
Dyspnea 
Chills 
Anaphylactoid reaction 
Infections: major 
minor 
Overall 
Percentages 
80 
60 
70 
20 
70 
o 
o 
40 
o 
Table IV. Morbidity and mortality in 52 liver transplant patients 
who were treated with OKT3 
Morbidity 
Mortality 
Fever 
Hemodynamic instability 
GI symptoms 
Dyspnea 
Chills 
Rash 
Anaphylactoid reaction 
Infections: major 
Overall' 
Group I 
Group 2 
Group 3 
minor 
No deaths attributable to OKT3. 
Percentages 
75 
62 
55 
32 
28 
20 
2 
15 
56 
23 
33(6/18) 
18 (4122) 
17 (2/18) 
mean follow-up has been 12.1 ± 1.5, 11.4 ± 2.0 and 
13.3 ± 1.4 months for groups 1,2, and 3, respectively. 
Morbidity. The majority of the side effects attributable 
to OKT3 were not life threatening (table IV). While 32% 
of the patients had subjective symptoms of shortness of 
breath, only 1 patient had severe bronchospasms requir-
ing intubation and ventilatory support. One patient had 
po 1 yarthralgias. 
Major infections occurred in 15% of the patients dur-
ing OKT3 therapy, including Pneumocystis carinii pneu-
monia in I patient and cytomegalovirus infections in two 
patients. Other major infections included bacterial sys-
temic sepsis, first diagnosed by the presence of bacter-
emia, which in all but I case was of graft origin. Urinary 
tract infections, cutaneous herpes simplex, and trivial 
wound infections were seen in 56% of the recipients 
(table II). Almost one third of the patients had cutaneous 
------------ --- ------------------------------- --------------------
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Fig. 7. Response of serum bilirubin (TBIL) 
and serum glutamic oxaloacetic transaminase 
(SGOT) in the patients of group 2, whose re-
jection was diagnosed between 10 days and 3 
months after liver replacement. The crosses 
indicate the loss of the graft, and the asterisk is 
on the curve of a patient who developed 
herpes virus hepatitis after OKT3 therapy. 
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herpes simplex at some point during or shortly after Table V. Response of liver recipients to OKT3 for reversal of 
OK T3 therapy _ acute rejection 
Mortality. The mortality in 52 liver transplant recip- -----------------------
No response Partial response Full response ients was 23% during the mean follow-up of 12.2 months. 
In the pediatric recipients, there was 25% mortality com-
pared with 22% in the adults. Patients in group I had an 
overall mortality of 33%, reflecting the gravity of their 
condition when OKT3 treatment was started. Patients in 
group 2 had a mortality of18%, while those in group 3 had 
a 17[Yo mortality. 
The deaths bore no obvious relation to OKT3 therapy. 
All 6 of the patients in group I who died had primary 
hepatic graft failure from the time of transplantation. In 
retrospect, the poor graft function in 2 cases was caused 
by hepatic artery thrombosis, while poor initial function 
in the other 4 recipients in group 1 may have been partly 
due to ischemia during procurement. Two of these six 
patients were considered too ill to have biopsies prior to 
starting OKT3 therapy. 
Two of the four patients who died in group 2 probably 
received damaged grafts. One of these 2 patients suffered a 
cerebral vascular accident, the other had a massive wound 
infection, and both developed serious infections of their 
liver grafts. A 3rd patient from group 2 died of metastases 
from his original hepatoma 7 months after therapy, with-
out evidence of rejection. The 4th patient died shortly after 
retransplantation for uncontrollable recurrent rejection, 6 
months after an initial reversal with 0 KT3. 
One death in group 3 occurred at retransplantation for 
chronic rejection that had not been reversed with OKT3. 
The other death was from systemic herpes zoster, 9 
months after OKT3 therapy. 
% % % 
Overall 22 25 53 
Group I 28 (5/18) 39 (7118) 33(6/18) 
Group 2 9 (2/22) 18 (4/22) 73 (16/22) 
Group 3 33 (4112) 25 (3/12) 42 (5/12) 
Response to OKT3 Therapy. The response rate was 
78%, with 53% of patients showing full reversal of rejec-
tion, while 25(Yt) had a partial response. The highest re-
sponse rate was in group 2, with a 91% incidence of 
objective improvement. This group also had the best 'full' 
response rate, with 73% of patients having resolution of 
all biochemical parameters of rejection. Evidence for 
reversal of rejection often was not obvious for 3 or 4 days, 
and continued improvement thereafter was the general 
rule (fig. 7). 
The individual serum bilirubin and transaminase lev-
els of group 2 patients before, during, and after therapy 
are shown in figure 7. Among the patients who responded 
to OKT3, there was a 52% decrease in total bilirubin from 
the onset to the termination of OKT3 therapy, with a 
further 27% reduction, to 21 % of pretreatment values, by 
the end of 2 months. Meanwhile, there were correspond-
ing 72% and 79% decreases in the serum glutamic oxalo-
acetic transaminase (fig. 7). 
In contrast, the recipients of group 1 treated in the first 
---~-----~-----
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Table VI. Predominant histologic findings in liver biopsies taken before or within 48 h of beginning OKT3 therapy 
Group 
2 
3 
n 
8 
22 
12 
Cell-mediated Chronic 
rejection rejection 
5 0 
19 I 
II 9 
Ischemic Ischemia plus Hepatitis Other 
injury rejection 
3 0 0 0 
----
0 0 I' 
-~~-~-~-
0 0 0 
This patient had evidence of bile duct obstruction, a diagnosis that was later confirmed. Secondary bile duct reconstruction was carried 
out successfully. 
9 postoperative days had only a 72% response rate, of 
which the response was more often partial than complete 
(table V). The failure rate was 28%. 
The total and partial response rates and the failure rate 
in the patients of group 3, who were treated after 3 
months posttransplant, were 42, 25, and 33% respectively 
(table V). 
Histopathologic Studies. Forty-one of the 52 patients 
had a needle biopsy of the liver prior to or shortly after 
initiation of OKT3 therapy. Cell-mediated rejection was 
documented in 95% (31/33) of group 2 and group 3 
patients (table VI). In addition, biopsies from group 3 
patients also had findings of chronic rejection in 75% of 
the specimens. In contrast, the 8 biopsies that were ob-
tained in group I patients had three examples of ischemic 
injury, with only slight - and in one case no - evidence of 
rejection. 
Follow-up biopsies at the end of the monoclonal ther-
apy were obtained in 24 of the liver recipients with pre-
treatment evidence of cell-mediated rejection (table VII). 
79% had improvement in the histologic picture following 
OKT3 therapy; 8% had no change, and in 8% of the 
biopsies, there was an increase in infiltrates or evidence 
of continued immune-mediated destruction. In addition, 
one patient developed evidence of herpes virus hepatitis 
following therapy. 
In patients who were rebiopsied, histopathologic evi-
dence of amelioration of acute rejection (fig. 4, 8) was 
commonly found, regardless of whether OKT3 therapy 
was started early, at an intermediate period, or late fol-
lowing transplantation (table VII). In one patient in 
group 2, there was improvement of rejection, but a histo-
logic picture developed that was consistent with viral 
hepatitis (OT 428). This patient subsequently developed 
abnormal liver function, which responded to intravenous 
acyclovir. The findings due to chronic rejection in pre-
treatment specimens did not change following OKT3 
therapy (fig. 6, 9). These persistent stigmata included loss 
Table VII. Histologic findings in 24 post-OKT3 liver biopsies in 
which pretreatment biopsies showed cellular rejection 
Group n 
2 
3 
Total 
5 
II 
8' 
24 
Histologic findings 
cellular rejection hepatitis 
improved no change worse 
4 
9 
6 
19 
o 
o 
2 o 
-~------~ 
2 2 
o 
02 
Evidence of chronic changes in pretreatment samples (6/8) did 
not change in posttreatment samples. 
The pre-OKT3 biopsy findings with cellular rejection: the find-
ings resolved post-treatment, but changes consistent with herpes 
hepatitis appeared. 
of bile ductules; arteriolar thickening; and portal, central 
vein, and sinusoidal fibrosis. 
In patients who underwent rebiopsy, the histopatho-
logic grading was prognostic of the clinical response to 
OKT3. Clinical improvement, despite a lack of histologic 
improvement, occurred in only 43% of cases. In contrast, 
there was a 94% correlation between improvement of the 
histologic picture and a favorable clinical response. By 
the X2 test, a statistically significant correlation between 
the change in the histologic pattern and the clinical out-
come was found (p < 0.01). 
Recurrence of Rejection. During the average follow-up 
of more than 12 months, only 10 (25(Vo) of the 40 patients 
who responded to OKT3 experienced further rejection 
episodes. The recurrent rejection episodes occurred a 
mean of 6.75 ± (SD) 3.25 months following completion of 
OKT3 (range, 0.5-12 months). Five of the ten recurrent 
rejections were successfully treated with high-dose ste-
a 
b 
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Fig. 8. Improvement of histologic findings of liver patient OT 
407, whose biopsy before OKT3 therapy is shown in figure 4. Note 
marked decrease of inflammatory cells after OKT3 therapy and 
intact bile ductule (arrow). a x 125. b x 315. 
roids. The other 5 patients subsequently lost their grafts 
and required retransplantation. 
After an average follow-up of 12.2 months, 35 (67%) of 
the 52 patients who received OKT3 therapy now have 
satisfactory hepatic function of their originally treated 
allograft. Group 1 patients have a 61% graft function rate, 
as compared with 77% in group 2 and only 33% in group 3. 
SerologiC Studies during OKT3 Therapy. An excess of 
OKT3 antibody was detected in al120 patients who were 
tested during therapy. The validity of this observation 
was confirmed by addition of test serum samples to 
normal lymphocytes, with subsequent binding of free 
OKT3 to these cells, as detected by complement-medi-
ated lymphocytotoxicity. 
Development of anti murine antibodies was also mon-
itored during and after 33 courses of OKT3. Prior to 
administration of OKT3, no anti murine antibody could 
Fig. 9. Improvement of histologic findings of liver patient OT 
377 after OKT3 therapy. The pretreatment biopsy is shown in 
figure 6. Note reduction of mononuclear cells. However, no bile 
ductules were seen in this biopsy, and there was an increase in 
centrilobular canalicular cholestasis. a x 125. b x 315. 
be detected in any patient. Afterwards 20 (61%) of the 33 
patients developed detectable antimurine antibodies, 
usually by day 12 after start of treatment. 
T-Cell Sub populations during OKT3 Therapy. Deple-
tion of T3-bearing T cells occurred during the first few 
days ofOKT3 administration (fig. lOa). A corresponding 
decrease in the number of total peripheral circulating 
lymphocytes could be demonstrated, to an average of 
76% of the pretreatment lymphocyte count on day 1 of 
therapy. Initially, there was concurrent depletion of T4-
and T8-bearing cells (fig. lOb), but antigenic modulation 
of the T3 receptor occurred, allowing expression of sig-
nificant percentages of T4-positive and T8-positive (but 
T3-negative) lymphocytes by 8 days after onset of OKT3 
therapy. Following cessation of monoclonal antibody 
administration, a prompt reappearance of the T3 marker 
occurred (fig. lOa). 
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Fig. 10. Influence ofOKT3 therapy on T-cell subpopulations in 
liver recipients during rejection. a Percent of total circulating lym-
phocytes that bear the T3 antigen as determined by direct immuno-
fluorescence (with standard deviations). b Percent of total circulat-
ing lymphocytes bearing T4 and T8 by direct immunofluorescence 
in the same patients as in a. Average number of observations per 
data point was 10. 
The large standard deviation of the percent of 
T3-bearing T cells seen in OKT3-treated liver patients 
was largely accountable by T-cell profiles of several pa-
tients, who had marked abnormalities in T-cell clearance, 
which resulted in a large percentage of residual circulat-
ing lymphocytes continuing to bear the T3 marker. An 
example of one such patient is shown in figure 11. A 
statistical correlation between the ability or inability to 
'clear' residual T3-bearing cells and clinical outcome 
could not be established, possibly because of the small 
sample size. Direct enumeration of lymphocytes, as de-
termined by incubating peripheral lymphocytes with flu-
orescein-conjugated antimouse IgG antibodies, con-
firmed the presence of a large number of OKT3-coated 
lymphocytes in the circulation of liver recipients 
throughout OKT3 therapy. 
Retreatment with OKT3. Three liver recipients were 
given a second full course of OKT3, 1-3 months after a 
first course. The second course was used to treat rejection 
of second grafts, which had been placed after the first 
grafts had failed in spite ofOKT3 therapy. Complete and 
long-term remission from rejection was accomplished in 
2 of the 3 patients without further episodes of recurrent 
rejection 3 and 6 months after completion of their second 
course of OKT3. In the unsuccessful case, the patient 
developed a high titer of anti murine antibodies during 
the second OKT3 course. This patient continued to reject 
the second liver but was successfully retransplanted with 
a third allograft 2 months later. 
The acute reactions to the mouse immunoglobulins 
were no more severe than in the average patient undergo-
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Fig. 11. Events in patient OT 469, whose biopsy-proved rejection 
was reversed with OKT3 therapy. Treatment was started on the 6th 
postoperative day. Note the persistence ofT3-positive lymphocytes 
in the circulation and T3 modulation during OKT3 therapy as well 
as the lymphocyte rebound after discontinuance of therapy. 
Cy A = Cic1osporin. GOT = glutamic oxaloacetic transaminase; 
GPT = glutamic pyruvate transaminase. 
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ing primary OKT3 therapy, but in the patient with anti-
murine antibodies, fever with simultaneous demonstra-
tion of rising titers of antimurine antibodies, and sero-
logic evidence of immune complexes supported the diag-
nosis of a delayed serum-sickness reaction. Renal func-
tion did not deteriorate, and this patient recovered 
promptly following discontinuance of OKT3. 
Discussion 
Heterologous antilymphoid serum (ALS) or its globu-
lin derivative, ALG, has been used clinically since 1966 
for the prevention or reversal of graft rejection [1]. The 
ability of ALG to 'erase' immunologic memory [37-39] 
was a particularly striking quality, which prompted 
Smith et a1. [40] and Lance and Medawar [41] to show how 
solid organs or skin grafts could be rescued from estab-
lished rejection in animal models. 
With monoclonal antibody preparations, the potent 
therapeutic qualities of ALG can be retained while the 
dangers of irrelevant foreign protein administration are 
reduced. Kung et al. [42] were able to produce mouse 
monoclonal antibodies directed against varying T-cell 
surface antigens [42]. They found that OKT3 reacted with 
more than 95% of peripheral, postthymic T cells without 
affecting immature thymocytes. Thus, the selective de-
pletion of peripheral T lymphocytes in our study and in 
other studies [19, 20] was not surprising. 
Despite the fact that the amount of heterologous im-
munoglobulin administered as monoclonal antibody is 
1150 to 11600 of that used with conventional polyclonal 
ALG, the side effects are not different from those re-
ported with the crude preparations more than 15 years 
ago [8, 9]. Fever, rashes, and gastrointestinal disturbances 
are probably not life-threatening, but reactions that were 
referred to as 'anaphylactoid' in the old literature [8, 9] 
have been a factor in at least 2 reported deaths during 
monoclonal treatment [21]. Typically, such reactions can 
occur up to several hours after ALG or OKT3 injection. 
Cardiovascular instability and symptoms or findings sug-
gestive of an acute asthmatic attack are ominous warn-
ings that emergency therapy with ventilator support, 
massive doses of steroids, and, more specifically, intrave-
nous epinephrine, may be required. It has been specu-
lated that release of lymphokines from the disrupted 
lymphocytes generates secondary amplification effects 
in widely distributed and biologically important target 
cells. 
The swift changes in lymphocyte traffic and dynamics 
help explain not only the toxicity but also the effective-
ness of OKT3 in the rapid reversal of renal allograft 
rejection, as described by Cosimi et al [19] and others [20, 
21]. In these earlier reports, in which baseline immuno-
suppression was with azathioprine and prednisone, a 
disquieting feature was a high rate of recurrent rejection, 
ranging from 50 to 80% shortly after completion of 0 KT3 
therapy. 
A factor that may have contributed to these recur-
rences was the systematic downward adjustment of the 
doses of azathioprine and prednisone during mono-
clonal therapy that was carried out primarily because of a 
fear of uncontrolled infection [19]. Instead of this prac-
tice, we have used the interval of OKT3 therapy as a 
breathing spell during which baseline immunosuppres-
sion therapy has been adjusted to an acceptable level that 
would be used chronically. 
Even more fundamentally, it may be suggested that 
the full value of OKT3 therapy could not be exploited 
using azathioprine and prednisone. With the more potent 
combination of ciclosporin and steroids, which was used 
clinically with OKT3 for the first time in this study, the 
prospect of reversing rejection with long subsequent peri-
ods of an enhanced survival under continuing ciclo-
sporin and steroids seemed brighter, providing there 
were not pharmacologic incompatibilities between the 
individual agents. The mechanism of ciclosporin is to 
block interleukin-2 synthesis by activated T cells with a 
consequent reduction ofT-cell proliferation [43]. Suthan-
thiran et al. [44] have reported that methylprednisolone 
can enhance the immunosuppressive capability of cyc-
losporine in vitro. While the in vivo effects of OKT3 are 
primarily immunosuppressive in nature, OKT3 has the 
converse effect of being mitogenic to an appropriate 
subpopulation of T cells in vitro [45] and, in addition, it 
can induce interleukin-2 secretion [46, 47]. Thus, it is 
conceivable that OKT3 could cancel the effects of being 
ciclosporin-steroid therapy. Fortunately, such fears of 
pharmacologic chaos have proved groundless, at least as 
judged by clinical observations of our patients, whose 
immunosuppression was demonstrably intensified by 
OKT3. 
The use of OKT3 with ciclosporin-steroids was not 
accompanied by an alarming increase of serious in-
fections as was feared when OKT3 was first added to 
azathioprine-steroid therapy [19, 48]. Although there was 
an increase in the incidence of viral infections during or 
shortly after completion of OKT3 therapy, these were 
limited for the most part to annoying localized herpes. 
No deaths have occurred among our renal transplant 
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recipients, and the 23% mortality among the liver recip-
ients from infections or other complications have not 
been, in any instance, directly attributable to specific 
toxicity from OKT3. 
In view of the relative safety of ciclosporin-steroid-
OKT3 therapy, the ability to control and reverse difficult 
rejections has been encouraging. In the renal allograft 
recipients who had been highly selected for their resis-
tance to steroid therapy, the salvage of organs was strik-
ing. Eight of ten renal grafts that were apparently lost to 
rejection recovered function - four completely and four 
partially. Furthermore, the benefit seemed long-lasting; 
the four patients with complete resolution have not had 
recurrent rejection during the follow-up period ranging 
from 10 to 12 months, although two of the four grafts with 
only a partial response slowly failed over the next few 
months. 
Analysis of the efficacy of OKT3 in reversal of acute 
rejection was more complex in the liver recipients. How-
ever, the conclusions were no less definite. In the 22 
patients in group 2, who developed rejection 10 days to 3 
months after transplantation, the ability of OKT3 to 
reverse rejection was marked. The rejections were con-
trolled in 91% of the 22 recipients. While 18% of these 
patients only had a partial response, 73% had complete 
resolution during or shortly after completion of OKT3 
therapy. Confidence in the clinical assessment was 
heightened by the good correlation between the clini-
cians' evaluation and the histopathologic studies of nee-
dle biopsies. Almost all of the biopsies, which were taken 
before OKT3 therapy, showed rejection, and improve-
ment in rejection criteria was the most common change 
seen in subsequent biopsies. The best clinical responses 
were in patients whose livers showed unequivocal histo-
logic changes of acute rejection as opposed to those 
whose liver showed significant chronic rejection or 
ischemic injury. 
The effectiveness of OKT3 therapy was also evident, 
although not as universal, in patients treated before 10 
days (group 1) and after 3 months (group 3). In group 1, 
not all of the patients suspected of having rejection actu-
ally had this diagnosis, but the needle biopsies necessary 
to clarify the situation were often considered too danger-
ous to be justifiable as a precondition of treatment. The 
most complex conditions for the use of OKT3 therapy 
were in the subgroup of group 1, in which patients devel-
oped severe hepatorenal complications during the first 
few postoperative days. Some such recipients probably 
did not yet have rejection, and it can be argued further 
that the testing of a new drug under such circumstances 
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created an unfair disadvantage for its evaluation. Yet the 
introduction of 0 K T3 into the therapeutic scheme at this 
time has already been life-saving in a number of in-
stances. By starting OKT3, it has been possible to mark-
edly decrease the intravenous ciclosporin component of 
therapy. This has allowed renal function to return with-
out the handicap of drug nephrotoxicity while ensuring 
that lethal rejection would not supervene. Even when a 
biopsy could not be obtained because of excessive risks, 
the OKT3 therapy could serve as a 'diagnostic trial', in 
which abrupt improvement of liver function was evi-
dence that a component of early hepatic dysfunction was 
due to rejection. In several patients who improved clin-
ically enough to allow a biopsy 1-3 days following initia-
tion of OKT3, residual lymphoid infiltration and other 
findings of rejection were still present. 
The patients in group 3, whose liver allografts under-
went rejection after 3 postoperative months, were given 
OKT3 with some hesitancy, since the biopsies of 75% of 
these patients showed evidence of chronic rejection in 
addition to acute changes, thereby limiting the function 
that could be restored. In spite of the artifact created by 
treating patients for rejection either very early or very late 
after transplantation, 67% of the recipients in the com-
bined groups 1 and 3 had either a partial or a complete 
restoration of graft function during OKT3 therapy, and 
only 2 patients had subsequent episodes of recurrent 
rejection. 
When our clinical trial with OKT31iver recipients was 
first started, randomization for the treatment of acute 
rejection was planned between monoclonal therapy ver-
sus high-dose steroids, both in conjunction with cic1os-
porin and prednisone. The inappropriateness of random-
ization was soon realized. Some of the patients consigned 
by chance to the OKT3 limb had rejections that might 
have responded easily to temporarily increased steroid 
therapy. Others with very severe rejections were commit-
ted by chance to an obviously futile and potentially 
dangerous trial with high-dose steroid therapy, from 
which rescue with OKT3 therapy was delayed. The neces-
sity for such frequent use of the OKT3 'safety net' in the 
steroid limb (table VIII) caused the randomized trial to 
be terminated. Our present policy is to treat all rejections 
with one or two 5-day bursts of high-dose steroid therapy. 
If this adjustment, plus careful adjustment of the ciclo-
sporin doses, does not bring a rejection under control, 
OKT3 is started. 
Observations in 3 of our patients have suggested the 
possibility of reusing OKT3. The possibility of retreat-
ment with OKT3 has been raised before [49] but, to our 
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Table VIII. Summary of OKT3 versus high-dose steroid 
randomization trials in reversal of acute liver rejection 
OKT3 
Prednisone 
n 
7 
11 
Reversal 
6 
4 
Rescue 
needed 
Rescue 
successful 
617 
Patients who did not respond to high-dose steroids were given a 
full course of OKT3 as rescue therapy. 
knowledge, has not been clinically tried. Two patients 
had complete reversal of rejection of second transplants. 
The third effort failed in a patient whose serum contained 
antimurine antibodies after the first course of OKT3. 
Thistlethwaite et al. [50] have described the use of cyclo-
phosphamide during OKT3 therapy to decrease the sen-
sitization rate, but have considered this effort at reduc-
tion of antibody formation to be dangerous. 
The first clinical trials of ciclosporin use by CaIne et al. 
[51] have opened a new era in transplantation. As more 
experience has been acquired with the use of ciclosporin, 
there has been a drift toward polypharmaceutical ther-
apy, which initially began by combining ciclosporin with 
steroids [52] and which will undoubtedly encompass in-
creasing use of monoclonal antibodies as these become 
commercially available. As was the case with the original 
double-drug and triple-drug regimens of azathioprine-
prednisone [53] and azathioprine-prednisone-ALG [38], 
it can be easier to work with smaller dose ranges of 
multiple agents than to work within the limitations im-
posed by the toxicity of any single agent. This will be 
particularly important with ciclosporin, a drug whose 
margin is fairly sharply defined by nephrotoxicity. 
NB: This analysis was attempted only for the first 62 liver and 
kidney recipients for whom minimal follow-ups of at least 9 months 
are available. An additional 26 renal recipients and 84 hepatic 
recipients have been treated from I week to 9 months prior to 
completion of this report. The early results in the more recent 110 
cases have been similar to the findings reported here. The total 
experience in the treatment of kidney rejection with 0 KT3 is given 
by Gordon et al. elsewhere in this symposium collection. 
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